ALEXANDRIA, Va. – Four noteworthy studies from the 2012 Gastrointestinal Cancers Symposium will be featured in an embargoed presscast for reporters on Tuesday, January 17, 2012, from 12:00-1:30 PM (EST). Highlighted studies will focus on the latest improvements being made in the detection and treatment of several gastrointestinal cancers. The presscast will be moderated by Morton Kahlenberg, MD, a member of the 2012 Gastrointestinal Cancers Symposium News Planning Team and ASCO’s Cancer Communications Committee.
During the presscast, which will be held via live teleconference and webinar, researchers will present results from the following four studies:
- A study evaluating use of optical biomarkers to detect individuals with Barrett’s esophagus who are at high risk of developing esophageal cancer (Randall Brand, MD, University of Pittsburgh)
- A trial analyzing effects of a targeted tyrosine kinase inhibitor agent, regorafenib, in patients with metastatic colorectal cancer who have progressed after standard therapies (Axel Grothey, MD, Mayo Clinic)
- An analysis of prognostic factors and use of the drug everolimus in a large study of patients with advanced neuroendocrine tumors (James Yao, MD, University of Texas’ M. D. Anderson Cancer Center)
- A study examining use of a blood serum-based test to detect early-stage pancreatic cancer (David Gold, PhD, Center for Molecular Medicine and Immunology/Garden State Cancer Center)
Gastrointestinal cancers include those of the colon/rectum, stomach, pancreas, esophagus, small intestine, anus and other digestive organs. In 2011, an estimated 278,000 people in the U.S. were diagnosed with these cancers, and an estimated 140,000 have died from them.1
This year’s Symposium will take place January 19-21, 2012, at The Moscone West Building in San Francisco and feature nearly 700 abstracts on the latest research in gastrointestinal cancers. On-site facilities for reporters will include a working newsroom and access to leading experts in the field.
Four leading medical specialty societies co-sponsor the three-day, multidisciplinary symposium, including the American Gastroenterological Association (AGA) Institute, the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO) and the Society of Surgical Oncology (SSO).
1 Cancer Facts & Figures 2011. Atlanta, GA; American Cancer Society: 2011.
Founded in 1964, the American Society of Clinical Oncology (ASCO) is the world’s leading professional organization representing physicians who care for people with cancer. With more than 35,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds groundbreaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit asco.org. Patient-oriented cancer information is available at Cancer.Net.